These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 31094186)

  • 1. Gene therapy of type 2 diabetes mellitus: state of art.
    Stafeev YS; Menshikov MY; Parfyonova YV
    Ter Arkh; 2019 Mar; 91(2):149-152. PubMed ID: 31094186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach.
    Nadeau DA
    Postgrad Med; 2013 May; 125(3):112-26. PubMed ID: 23748512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Potential of Lentivirus-Mediated Glucagon-Like Peptide-1 Gene Therapy for Diabetes.
    Tasyurek HM; Altunbas HA; Balci MK; Griffith TS; Sanlioglu S
    Hum Gene Ther; 2018 Jul; 29(7):802-815. PubMed ID: 29409356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current therapies and targets for type 2 diabetes mellitus.
    Chellappan DK; Yap WS; Bt Ahmad Suhaimi NA; Gupta G; Dua K
    Panminerva Med; 2018 Sep; 60(3):117-131. PubMed ID: 29696964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Present and potential future use of gene therapy for the treatment of non-insulin dependent diabetes mellitus (Review).
    Freeman DJ; Leclerc I; Rutter GA
    Int J Mol Med; 1999 Dec; 4(6):585-92. PubMed ID: 10567666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluation of the therapeutic effect of metformin monotherapy with metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients.
    Firouzjaei A; Li GC; Wang N; Liu WX; Zhu BM
    Nutr Diabetes; 2016 May; 6(5):e209. PubMed ID: 27136447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene and cell therapies for diabetes mellitus: strategies and clinical potential.
    Giannoukakis N; Robbins PD
    BioDrugs; 2002; 16(3):149-73. PubMed ID: 12102644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats.
    Lee Y; Kwon MK; Kang ES; Park YM; Choi SH; Ahn CW; Kim KS; Park CW; Cha BS; Kim SW; Sung JK; Lee EJ; Lee HC
    J Gene Med; 2008 Mar; 10(3):260-8. PubMed ID: 18085721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current management of diabetes mellitus and future directions in care.
    Chatterjee S; Davies MJ
    Postgrad Med J; 2015 Nov; 91(1081):612-21. PubMed ID: 26453594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 2 diabetes and metabolic syndrome - adipokine levels and effect of drugs.
    Farooq R; Amin S; Hayat Bhat M; Malik R; Wani HA; Majid S
    Gynecol Endocrinol; 2017 Jan; 33(1):75-78. PubMed ID: 27705028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promising new approaches.
    Reasner CA
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetics of type 2 diabetes mellitus.
    Malecki MT
    Diabetes Res Clin Pract; 2005 Jun; 68 Suppl1():S10-21. PubMed ID: 15955369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neu-P11, a novel MT1/MT2 agonist, reverses diabetes by suppressing the hypothalamic-pituitary-adrenal axis in rats.
    Zhou J; Zhang J; Luo X; Li M; Yue Y; Laudon M; Jia Z; Zhang R
    Eur J Pharmacol; 2017 Oct; 812():225-233. PubMed ID: 28687198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Branched Chain Amino Acids Are Associated with Insulin Resistance Independent of Leptin and Adiponectin in Subjects with Varying Degrees of Glucose Tolerance.
    Connelly MA; Wolak-Dinsmore J; Dullaart RPF
    Metab Syndr Relat Disord; 2017 May; 15(4):183-186. PubMed ID: 28437198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
    Hare KJ
    Dan Med Bull; 2010 Sep; 57(9):B4181. PubMed ID: 20816021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
    Henkel E; Menschikowski M; Koehler C; Leonhardt W; Hanefeld M
    Metabolism; 2005 Sep; 54(9):1168-73. PubMed ID: 16125528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
    Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
    Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in obestatin gene and GPR39 receptor expression in peripheral tissues of rat models of obesity, type 1 and type 2 diabetes.
    Kolodziejski PA; Pruszynska-Oszmalek E; Sassek M; Kaczmarek P; Szczepankiewicz D; Billert M; Mackowiak P; Strowski MZ; Nowak KW
    J Diabetes; 2017 Apr; 9(4):353-361. PubMed ID: 27106635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.